Yatai Pharmaceutical announced that it recently received the Drug Supplementary Application Approval Notice for Spironolactone Tablets issued by the National Medical Products Administration. The 25 mg strength of the drug has passed the generic drug quality and efficacy consistency evaluation. Spironolactone tablets are indicated for edematous conditions, hypertension, primary aldosteronism, and the prevention of hypokalemia. Passing this consistency evaluation will enrich the company's product pipeline, enhance market competitiveness, and accumulate experience for subsequent consistency evaluations of other products.
Zhejiang Yatai Pharmaceutical Co LtdPassing generic drug consistency evaluation enhances competitiveness and pipeline.